JESSE JAMES8832
commented on
$Aquestive Therapeutics(AQST.US$
NEWS
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Positive
Successful completion of Phase 3 study for Anaphylm in Q1 2024
Received FDA approval for Libervant for patients ages two to five
Extended cash runway into 2026 through underwritten public offering
Progressed clinical studies for AQST-108 in dermatology conditions
Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024
Negati...
NEWS
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Positive
Successful completion of Phase 3 study for Anaphylm in Q1 2024
Received FDA approval for Libervant for patients ages two to five
Extended cash runway into 2026 through underwritten public offering
Progressed clinical studies for AQST-108 in dermatology conditions
Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024
Negati...
1
3
JESSE JAMES8832
liked and commented on
$Gossamer Bio(GOSS.US$ Gossamer Bio Inc: $396 Mln in Cash, Cash Equivalents & Marketable Securities, as of March 31, 2024! Enough to fund operations into Q1 2027
2
7
JESSE JAMES8832
reacted to
$FibroGen(FGEN.US$ Upcoming Milestones:
Pamrevlumab
•Topline data from the PanCAN Precision PromiseSM Phase 2/3 study of pamrevlumab in metastatic pancreatic cancer expected in mid-2024, reflecting PanCAN’s updated timing to complete database lock and subsequent analysis of the topline results by the independent Statistical Monitoring Committee.•Topline data from the LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic can...
Pamrevlumab
•Topline data from the PanCAN Precision PromiseSM Phase 2/3 study of pamrevlumab in metastatic pancreatic cancer expected in mid-2024, reflecting PanCAN’s updated timing to complete database lock and subsequent analysis of the topline results by the independent Statistical Monitoring Committee.•Topline data from the LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic can...
2
JESSE JAMES8832
commented on
JESSE JAMES8832
commented on
$Lucid Diagnostics(LUCD.US$ Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing
PR Newswire· 2 mins ago
PR Newswire· 2 mins ago
1
2
JESSE JAMES8832
reacted to
$ImmunityBio(IBRX.US$ ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient For 170,000 Doses Of ANKTIVA
Benzinga· 2 mins ago
ANKTIVA Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product
ImmunityBio's 400,000 square foot GMP fill-finish facility in Dunkirk, New York on track to be completed in 12-18 months with capacity to produce a million vials annually
Coupled with a recent announcement of BCG availabilit...
Benzinga· 2 mins ago
ANKTIVA Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product
ImmunityBio's 400,000 square foot GMP fill-finish facility in Dunkirk, New York on track to be completed in 12-18 months with capacity to produce a million vials annually
Coupled with a recent announcement of BCG availabilit...
4
JESSE JAMES8832
reacted to
$Esperion Therapeutics(ESPR.US$ 30 minute rule in effect! Hehehe
4
5
JESSE JAMES8832 : let it get beat down so i can buy it up
JESSE JAMES8832 Jaguar8OP: at least i get my way somehow llol